Press Detail

Nutcracker Therapeutics Named Industry Veteran Samuel Deutsch as Chief Scientific Officer


EMERYVILLE, Calif., January 8, 2024 — Nutcracker Therapeutics, Inc., a biotechnology company dedicated to developing transformative RNA therapies through its proprietary platform, today announced the promotion of Samuel Deutsch, Ph.D., as the company’s chief scientific officer (CSO). Dr. Deutsch has been a part of the Nutcracker team since its inception, and previously served as its executive vice president of Research and Early Development, a role he has held for more than two years.

“I’m thrilled to assume my new role, and to continue leading Nutcracker’s research team through a new era of growth and innovation,” said Dr. Deutsch. “As we continue to build upon our prior work in RNA drug development, I look forward to sharing with the scientific community our work on new drug programs with novel mRNA modalities and improvements to our core technology platform in the coming months.”

Dr. Deutsch’s previous roles at Nutcracker include vice president of Biology and senior vice president of Research and Early Development. Before joining Nutcracker, Dr. Deutsch was a research scientist at Lawrence Berkeley Lab and led the DNA synthesis foundry at the Joint Genome Institute. His experience also includes leading research in molecular hematology at the Geneva University Hospital, and cancer genomics at the World Health Organization.

“Sam has brought invaluable experience and leadership to Nutcracker since its establishment in 2018,” said Igor Khandros, CEO. “His expertise will prove instrumental as we head into this pivotal year for our company, in which our lead mRNA drug candidate, NTX-250, will enter clinical trials. I’m confident in his ability to lead our scientific team with excellence.”

Dr. Deutsch earned a bachelor’s degree in genetics from the University of Nottingham, and received his Ph.D. in molecular medicine from the University of Geneva. He also completed a postdoc in synthetic biology and genomics from the Lawrence Berkeley National Laboratory. He has authored more than 75 peer-reviewed papers and has several patents to his name.

About Nutcracker Therapeutics, Inc.
Nutcracker Therapeutics, Inc., is an RNA therapeutics company that has combined the power of advanced engineering with high-precision biosynthesis to deploy a complete RNA platform that encompasses the design, delivery, and manufacturing of RNA medicines. Armed with this high-tech advantage, the company has initiated multiple therapeutic programs with the support of clinical investigators at leading institutions. Nutcracker Therapeutics’ technology platform has the potential to significantly reduce costs and cycle times for RNA therapeutic development, with dramatic advantages in speed and capacity scaling over other RNA manufacturing approaches.

For more information, visit

Media Contact
Maggie Williard
(908) 914-6091